Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3Terminated 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1

Conditions

Sarcoma 1Multiple Myeloma 1Liposarcoma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Nelfinavir × Clear all
NCT01555281 2022-07-07

Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma

Swiss Cancer Institute

Phase 1/2 Terminated
33 enrolled
Plasma cell

Multiple Myeloma

NCT00233948 2015-04-01

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

City of Hope Medical Center

Phase 1/2 Terminated
29 enrolled 7 charts
Sarcoma

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡